Bxcl501
Chronic Otitis Media
Nationwide Children's HospitalPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Chronic Otitis Media cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MIDAZOLAM Nationwide Children's Hospital | Phase 2/3 | B |
FENTANYL Nationwide Children's Hospital | Phase 2/3 | B |
Same molecule, other indications
Bxcl501 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →